Form 4: Lyell Immunopharma Director Elizabeth Nabel Acquires 130,000 Stock Options
SEC Form 4 Filing
Director Elizabeth Nabel acquired 130,000 stock options in Lyell Immunopharma, Inc. on May 15, 2025, vesting dependent on continued service.
Summary
- On May 15, 2025, Elizabeth G. Nabel, a director of Lyell Immunopharma, Inc., acquired 130,000 stock options.
- The exercise price of these options is $0.4017.
- The options vest on the earlier of the next annual meeting of stockholders following May 15, 2025, or the first anniversary of May 15, 2025, contingent on continuous service as a director.
- The options expire on May 14, 2035.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock option acquisition by a director, with no inherent positive or negative implications.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions and provides transparency to the market regarding the holdings of company directors.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of earliest transaction: Elizabeth Nabel acquired 130,000 stock options. |
| 05/15/2025 | Date the option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date. |
| 05/14/2035 | Expiration date of the options. |
| 05/19/2025 | Date of signature by Attorney-in-Fact. |
Keywords
stock options, Form 4, Lyell Immunopharma, director, beneficial ownership, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.